Halozyme sets out offer to acquire Evotec

Halozyme Therapeutics said on Thursday it has proposed to buy German drug developer Evotec for about 2 billion euros ($2.10 billion), ...

Halozyme Therapeutics has bid to buy Evotec for around 2 billion euros ($2.1 billion). Evotec confirmed it received an offer and said it is ...

(NASDAQ: HALO) ("Halozyme" or the "Company") confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of ...

The San Diego biotech made an unsolicited bid to buy Evotec. Elsewhere, BeiGene recast itself as BeOne Medicines in a change meant to reflect ...

Halozyme's offer comes as Evotec deals with several business setbacks and a languishing stock price. Earlier this year, Evotec implemented a ...

... Evotec SE has attracted takeover interest from Nasdaq-listed biotech firm Halozyme Therapeutics Inc. for a deal that would value the German ...

The acquisition would combine Halozyme's advanced drug delivery technology with Evotec's drug discovery platform. The proposed combination ...

Halozyme offered to acquire Evotec for €11 per share (€2 billion total) ... the Halozyme offer. San Diego-based Halozyme makes drug ...

Evotec SE has attracted takeover interest from Nasdaq-listed biotech firm Halozyme Therapeutics Inc. for a deal that would value the German ...

Halozyme intends to purchase all the shares of Evotec at 11 euros per share, which represents a premium of 27.5% to Evotec's last close price.

Shares of German drug discovery company Evotec leapt 20% to 10.33 euros this morning on the revelation that the USA's Halozyme Therapeutics ...

On Thursday, Halozyme Therapeutics, Inc. (NASDAQ:HALO) submitted a non-binding proposal to Evotec SE (NASDAQ:EVO) to acquire the German ...

... Halozyme Therapeutics Inc., people familiar with the matter said ... Halozyme has recently expressed interest in acquiring Evotec at ...

(RTTNews) - Halozyme Therapeutics Inc. (HALO) confirmed it has submitted a non-binding proposal to the Management Board and Supervisory ...

Halozyme might be about to undergo its second transformation, on Thursday making official a bid to acquire the German drug discovery ...

Halozyme (NASDAQ: HALO) has submitted a non-binding proposal to acquire Evotec SE (NASDAQ: EVO) for €11.00 per share in cash, valuing the ...

... ) announced on Thursday its plans to acquire German drug developer Evotec SE ADR (NASDAQ:EVO) in a deal valued at approximately 2 billion eur.

According to the press release, the proposed deal would leverage Halozyme's strong cash generation and balance sheet to invest in Evotec's ...

Halozyme Therapeutics submitted a bid to acquire German drug developer Evotec in a deal with an equity value of 2 billion euros ($2.11 billion.).

Evotec's shares climbed as much as 23% on Friday after the company received an unsolicited takeover proposal from Halozyme Therapeutics ...